Indication
Pancreatic Acinar Cell Carcinoma
7 clinical trials
11 products
6 drugs
Clinical trial
SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard DerivativesStatus: Recruiting, Estimated PCD: 2025-12-01
Product
BCNUProduct
MelphalanProduct
Vitamin B12Product
Vitamin CProduct
EthanolClinical trial
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationStatus: Recruiting, Estimated PCD: 2027-10-31
Product
OlaparibProduct
PlaceboClinical trial
Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- GemcitabineStatus: Active (not recruiting), Estimated PCD: 2013-01-22
Drug
ErlotinibDrug
GemcitabineProduct
VismodegibClinical trial
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)Status: Recruiting, Estimated PCD: 2029-01-15
Product
Nab paclitaxelDrug
CisplatinClinical trial
Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)Status: Active (not recruiting), Estimated PCD: 2021-09-02
Product
FalimarevProduct
InalimarevDrug
GM-CSFClinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Drug
LurbinectedinDrug
T-VEC